property and lipase resolution ability in the development of a new resolution process for preparing optically pure carboxylic acids. With the Candida antarctica lipase B (CALB)-catalyzed hydrolysis of (R,S)-N-profenylazoles in organic solvents as the model system, (R,S)-N-profenyl-1,2,4-triazoles instead of their corresponding ester analogues were exploited as the best substrates for preparing optically
FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE
申请人:Bezwada Rao S.
公开号:US20090105352A1
公开(公告)日:2009-04-23
This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.
[EN] NIACIN DERIVATIVES USEFUL TO TREAT METABOLIC SYNDROMES<br/>[FR] DÉRIVÉS DE NIACINE UTILES POUR TRAITER DES SYNDROMES MÉTABOLIQUES
申请人:SCHERING CORP
公开号:WO2010009212A1
公开(公告)日:2010-01-21
The present invention provides compounds of the Formula I: (I) wherein R' represents a recoverable residue of a non-steroidal anti-inflammatory drug (NSAID); and G represents a hydrolysable or metabolizable linker group; and salts, solvates, esters and prodrugs thereof, as well as pharmaceutical compositions containing them, and methods of using them to treat metabolic syndrome, dyslipidemia, cardiovascular diseases, disorders of the peripheral and central nervous system, hematological diseases, cancer, inflammation, respiratory diseases, gastroenterological diseases, diabetes, and non-alcoholic fatty liver diseases.
CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS
申请人:Bezwada Rao S.
公开号:US20090076174A1
公开(公告)日:2009-03-19
The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.
The application relates to a process which comprises:
A)forming a reaction product composition comprising arylcarboxylic acid or substituted arylcarboxylic acid in a polar organic solvent medium by palladium-catalyzed hydrocarboxylation of an arylolefin or substituted arylolefin in a liquid medium comprising polar organic solvent, water, HCl, and at least one ether;
B)mixing with said reaction product composition an aqueous solution of inorganic base to form a mixture comprising an aqueous phase containing dissolved inorganic salt of said arylcarboxylic acid or substituted arylcarboxylic, and before and/or during and/or after such mixing, distilling a substantial portion of the ether from the reaction mixture, such that a mixture of residual organic phase and such aqueous phase remain as a distillation residue;
C)separating the phases from each other;
D)distilling residual organic impurities from the aqueous phase and providing an aqueous solution having a concentration in the range of 10 and 35 wt%, by, if necessary, adjusting the concentration of such aqueous solution by removal therefrom or addition thereto of water;
E)washing the aqueous solution with non-polar organic solvent at least twice;
F)mixing non-oxidizing mineral acid with the aqueous phase in the presence of non-polar liquid solvent to form (i) an organic phase composed of a solution of arylcarboxylic acid or substituted arylcarboxylic acid in non-polar liquid organic solvent and (ii) an aqueous phase;
G)separating the phases from each other; and
H)crystallizing arylcarboxylic acid or substituted arylcarboxylic acid from organic solvent.